An insulin degludec hexamer. A chains are chartreuse, B chains are tan, and the central zinc atom is teal. From PDB: 4AKJ.
Clinical data
Trade names
Tresiba
AHFS/Drugs.com
Monograph
MedlinePlus
a615055
License data
US DailyMed: Insulin degludec
Pregnancy category
AU: B3
Routes of administration
Subcutaneous
ATC code
A10AE06 (WHO)
Legal status
Legal status
AU: S4 (Prescription only)[1][2][3]
CA: ℞-only[4]
US: ℞-only[5]
EU: Rx-only[6]
In general: ℞ (Prescription only)
Identifiers
IUPAC name
B29N(ε)-ω-carboxypentadecanoyl-γ-L-glutamyl desB30 human insulin
CAS Number
844439-96-9N
PubChem SID
124490467
ChemSpider
none
UNII
54Q18076QB
KEGG
D09727N
Chemical and physical data
Formula
C274H411N65O81S6
Molar mass
6104.04 g·mol−1
NY (what is this?)(verify)
Insulin degludec (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Tresiba.[7] It is administered via subcutaneous injection to help control the blood sugar level of those with diabetes. It has a duration of action that lasts up to 42 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir), making it a once-daily basal insulin,[8][9][10] that is one that provides a base insulin level, as opposed to the fast- and short-acting bolus insulins.
Insulin degludec is a modified insulin that has one single amino acid deleted in comparison to human insulin, and is conjugated to hexadecanedioic acid via gamma-L-glutamyl spacer at the amino acid lysine at position B29.
It is included on the World Health Organization's List of Essential Medicines[11] as an equivalent to insulin glargine. In 2021, it was the 146th most commonly prescribed medication in the United States, with more than 4million prescriptions.[12][13]
^"Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 9 April 2023.
^"Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
^"Diabetic health". Health Canada. 8 May 2018. Retrieved 13 April 2024.
^"Tresiba- insulin degludec injection, solution". DailyMed. 1 July 2022. Archived from the original on 7 July 2022. Retrieved 11 February 2024.
^"Tresiba EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 22 January 2021. Retrieved 15 January 2021.
^Cite error: The named reference CHMP2012 was invoked but never defined (see the help page).
^Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T (May 2007). "Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes". Diabetes, Obesity & Metabolism. 9 (3): 290–299. doi:10.1111/j.1463-1326.2006.00685.x. PMID 17391154. S2CID 23810204.
^Haahr H, Heise T (September 2014). "A review of the pharmacological properties of insulin degludec and their clinical relevance". Clinical Pharmacokinetics. 53 (9): 787–800. doi:10.1007/s40262-014-0165-y. PMC 4156782. PMID 25179915.
^"Tresiba Summary of product characteristics" (PDF). European Medicines Agency. Archived (PDF) from the original on 4 March 2016. Retrieved 29 September 2014.
^World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
^"The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
^"Insulin Degludec - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
Insulindegludec (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Tresiba. It is administered...
clinically significant difference when comparing insulin glargine to NPH insulin, insulin detemir or insulindegludec in the management of type I Diabetes in neither...
(Lantus) Insulin detemir (Levemir) Insulindegludec (Tresiba) Insulindegludec is sometimes classed separately as an "ultra-long" acting insulin due to...
of the previous longest-acting insulin analogue insulindegludec), making it a once-weekly basal insulin. Like insulin, icodec is composed of two peptide...
NPH insulin to other insulin analogues (insulin detemir, insulin glargine, insulindegludec) in both children and adults with Type 1 diabetes. Insulin detemir...
also compared the effects of insulin detemir to NPH insulin and other insulin analogues (insulin glargine, insulindegludec) in both children and adults...
in conjunction with insulin therapy.[citation needed] Mainly used in Type II diabetes, metformin is considered to increase insulin sensitivity in vivo...
sulfonylurea family of medications. It works mostly by increasing the release of insulin. Gliclazide was patented in 1966 and approved for medical use in 1972....
Insulin aspart, sold under the brand name NovoLog, among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. It is...
Giorgio; Silver, Robert (August 2019). "Durability of insulindegludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type...
tirzepatide was observed to be superior to dulaglutide, semaglutide, degludec, and insulin glargine with regards to glycemic efficacy and obesity reduction...
to enhance growth of pancreatic beta cells, which are responsible for insulin production and release. Additionally, it inhibits the production of glucagon...
receptor agonist) also known as incretin mimetics. It works by increasing insulin release from the pancreas and decreases excessive glucagon release. Common...
diabetes; its mode of action is to increase insulin secretion by the pancreas. However it requires adequate insulin synthesis as prerequisite to treat appropriately...
diabetes. Glycemic control and safety were found to be similar to insulindegludec in a phase II trial. Heise, Tim; Chien, Jenny; Beals, John M.; Benson...
It works by decreasing glucose production in the liver, increasing the insulin sensitivity of body tissues, and increasing GDF15 secretion, which reduces...
increasing secretion of insulin from the beta cells in the pancreas. Sulfonylureas are ineffective where there is absolute deficiency of insulin production such...
being unable to produce insulin and one of the actions of dulaglutide is to stimulate functioning islet cells to produce more insulin. Dulaglutide can be...
peptidase-4 (DPP-4) inhibitor class and works by increasing the production of insulin and decreasing the production of glucagon by the pancreas. Sitagliptin...
resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs. Nateglinide is contraindicated...
Lente insulin (from Italian lento, "slow"; also called insulin zinc suspension) was an intermediate duration insulin that is no longer used in humans....
Global Information
(what is this?) (verify)